PREVIEW-Analysts expect Dr Reddy's to post first profit drop in five quarters

Analysts expect India's Dr Reddy's REDY.NS to post a 23% Y/Y decline in Q3 profit to 10.89 billion rupees ($119.70 million), 0.4% gain in revenue to 84.17 billion rupees - data compiled by LSEG

Rev growth seen crawling to nearly 8-year low, while profit to fall for first time in five quarters - data compiled by LSEG

REDY's revenue from key U.S. market pressured by reduced contribution from Lenalidomide, REDY's copycat version of Bristol-Myers Squibb's BMY.N popular cancer drug Revlimid and weak pricing of drugs across its base generics business, analysts say

REDY gets a third of revenue from North America, about one fifth from India

Investors to look out for commentary on launch of generic version of weight loss drug Semaglutide

Stock dropped 8.4% in 2025 vs Pharma index's ~3% drop

($1 = 90.9770 Indian rupees)